OUR SCIENCE
Advancing treatment of solid tumors with
tumor-restricted transgene expression
Exploiting our expertise in cell and gene therapy, Genenta have developed a proprietary technology that triggers the production of therapeutics inside tumors, allowing a robust anti-cancer response with minimized systemic toxicity. The therapeutic payload is codified by a DNA sequence that is expressed, by a subset of tumor-infiltrating monocytes called Tie-2 expressing monocytes (TEMs). This technology is widely applicable across all solid cancers characterized by the presence of intratumoral TEMs. Our clinical leading product candidate, Temferon™, delivers alpha-interferon as therapeutic, specifically boosting the antigenicity of cancer epitopes within the tumor microenvironment.